Browsing by Author "Galindo A., Héctor"
Now showing 1 - 11 of 11
Results Per Page
Sort Options
- ItemA Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability(2020) Pinto Paganini, Mauricio Arturo; Bravo Castillo, Maria Loreto; Sánchez Rojel, César Giovanni; Acevedo, Francisco; Mondaca Contreras, Sebastián Patricio; Ibañez, Carolina; Galindo A., Héctor; Madrid Arenas, Jorge; Nervi Nattero, Bruno; Peña Durán, José Esteban; Torres Montes, Paula Javiera; Owen, Gareth Ivor; Corvalán R., Alejandro; Garrido S., Marcelo; Córdova Delgado, M.; Retamal, I. N.; Muñoz Medel, M.; Durán, D.; Villanueva, F.; Koch, E.; Armisen, R.
- ItemCáncer de mama metastásico. Caracterización de una cohorte según subtipos(2014) Sánchez Rojel, César Giovanni; Acevedo Claros, Francisco Nicolás; Petric, G. M.; Galindo A., Héctor; Domínguez Covarrubias, Francisco José; León Ramírez, Augusto; Razmilic Valdés, Dravna Nichi; Espinoza, F.
- ItemCaracterísticas clínicas y pronóstico de pacientes con cáncer de mama HER2 positivo avanzado, en la era antes y después de terapias anti-HER2.(2018) Sánchez Rojel, César Giovanni; Domínguez Covarrubias, Francisco José; Galindo A., Héctor; Camus Appuhn, Mauricio Gonzalo; Oddo Benavides, David; Villarroel, Alejandra; Razmilic Valdés, Dravna Nichi; Navarro Ortega, María Elena; Pérez Sepúlveda, Alejandra Andrea; Medina Araya, Lidia; López, Valeska; Acevedo Claros, Francisco Nicolás
- ItemChilean Gastric Cancer Task Force : a study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients(2018) Owen, Gareth Ivor; Pinto, Mauricio P.; Retamal, Ignacio N.; Fernández, María F.; Cisternas, Betzabe; Mondaca Contreras, Sebastián Patricio; Sánchez Rojel, César Giovanni; Galindo A., Héctor; Nervi, Bruno; Ibáñez Cáceres, Carolina; Acevedo Claros, Francisco Nicolás; Madrid Arenas, Jorge; Peña, José; Bravo Castillo, María Loreto; Maturana, María, José; Córdova Delgado, Miguel; Romero, Diego; De la Jara, Nathaly; Torres Montes, Paula Javiera; Rodríguez Fernández, María; Espinoza Sepúlveda, Manuel Antonio; Balmaceda, Carlos; Freire, Matías; Gárate Calderón, Valentina; Crovari Eulufi, Fernando; Jiménez Fonseca, Paula; Carmona Bayonas, Alberto; Zwenger, Ariel; Armisen, Ricardo; Corválan, Alejandro H.; Garrido Salvo, Marcelo; Owen, Gareth Ivor; Pinto, Mauricio P.; Retamal, Ignacio N.; Fernández, María F.; Cisternas, Betzabe; Mondaca, Sebastián; Sánchez Rojel, César Giovanni; Galindo Aranibar, Héctor Gonzalo; Nervi, Bruno; Ibáñez Cáceres, Carolina; Acevedo Claros, Francisco Nicolás; Madrid, Jorge; Peña, José; Bravo, María, Loreto; Maturana, María, José; Córdova Delgado, Miguel; Romero, Diego; De la Jara, Nathaly; Torres, Javiera; Rodríguez Fernández, María; Espinoza Sepúlveda, Manuel Antonio; Balmaceda, Carlos; Freire, Matías; Gárate Calderón, Valentina; Crovari Eulufi, Fernando; Jiménez Fonseca, Paula; Carmona Bayonas, Alberto; Zwenger, Ariel; Armisen, Ricardo; Corválan, Alejandro H.; Garrido, Marcelo
- ItemChilean Registry for Neuroendocrine Tumors: A Latin American Perspective(2019) Pinto, Mauricio P.; Muñoz Medel, Matías; Carrillo, Diego; Retamal, Ignacio N.; Bravo Castillo, María Loreto; Nervi Nattero, Bruno; Sánchez Rojel, César Giovanni; Galindo A., Héctor; Ibáñez Cáceres, Carolina; Peña Durán, José Esteban; Madrid Arenas, Jorge; Valenzuela, Yasna; Balmaceda, Carlos; Briones, Juan; Torres Montes, Paula Javiera; Nilo, Flavia; Guarda Vega, Francisco; Quintana, Juan Carlos; Orellana, Pilar; Mondaca Contreras, Sebastián Patricio; Acevedo Claros, Francisco Nicolás; Vicentini, Daniel; Córdova Delgado, Miguel; Owen, Gareth Ivor; Garrido Salvo, Marcelo
- ItemClinico-pathologic subtypes of breast cancer primary tumors are related to prognosis after recurrence(2016) Sánchez Rojel, César Giovanni; Camus Appuhn, Mauricio Gonzalo; Medina Araya, Lidia; Oddo Benavides, David; Artigas, Rocío; Pérez Sepúlveda, Alejandra Andrea; Domínguez Covarrubias, Francisco José; Razmilic Valdés, Dravna Nichi; Navarro Ortega, María Elena; Galindo A., Héctor; Acevedo Claros, Francisco Nicolás
- ItemComplete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor(2014) Quezada Sanhueza, Nicolás; Acevedo Claros, Francisco Nicolás; Marambio, A.; León, F.; Galindo A., Héctor; Roa Strauch, Juan Carlos Enrique; Jarufe Cassis, NicolásINTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.INTRODUCTION Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib are the mainstay treatment in the management of advanced or metastatic GIST. Complete pathological response to these agents is an extremely rare event, especially in the case of EGIST due to its more aggressive behavior reported. PRESENTATION OF CASE Here we describe the case of a 61 years old woman, with an advanced GIST, who was operated after 10 months of Imatinib mesylate. The biopsy demonstrated the extra intestinal location of the tumor and a complete pathological response was confirmed. DISCUSSION Complete pathological response to Imatinib is a rare event. To our knowledge, this is the first report of complete response in an EGIST. New clinical, radiological and metabolic criteria of tumoral response to neoadjuvant treatment are revised. CONCLUSION EGIST complete pathological response to Imatinib can be achieved. However, recommendation of systematic neoadjuvant therapy with Imatinib remains investigational and more studies are warranted in the future.
- ItemMammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution(2020) Maiz, Cristóbal; Silva Vargas, Fernando; Domínguez Covarrubias, Francisco José; Galindo A., Héctor; Camus Appuhn, Mauricio Gonzalo; León Ramírez, Augusto; Oddo Benavides, David; Villarroel, A; Razmilic Valdés, Dravna Nichi; Navarro Ortega, María Elena; Medina, L.; Merino Lara, Tomas Rodrigo; Vines, E; Pena, J; Maldonado, D; Pinto, MP; Acevedo Claros, Francisco Nicolás; Sanchez, C
- ItemRetrospective analysis of chilean and Mexican GI stromal tumor registries : a tale of two Latin American realities(2020) Calderillo, G.; Galindo A., Héctor; Nervi Nattero, Bruno; Madrid Arenas, Jorge; Sánchez Rojel, César Giovanni; Ibáñez, Carolina; Peña Durán, José Esteban; Mondaca Contreras, Sebastián Patricio; Acevedo Claros, Francisco Nicolás; Garrido S., Marcelo; Muñoz-Medel, M.; Carbajal, E.; Córdova-Delgado, M.; Durán, D.; Retamal, I. N.; Fernández, P.; Espinoza, A.; Salas, R.; Paz Mastretta, M. de la; Koch, E.; Pinto, M. P.
- ItemSurvival rates of advanced estrogen-receptor positive breast cancer : Analysis of 211 cases(2020) Sánchez Rojel, César Giovanni; Domínguez Covarrubias, Francisco José; Galindo A., Héctor; Camus Appuhn, Mauricio Gonzalo; Oddo Benavides, David; Razmilic Valdés, Dravna Nichi; Pena Duran, José Esteban; Navarro Ortega, María Elena; Medina Araya, Lidia; Merino Lara, Tomas Rodrigo; Acevedo Claros, Francisco Nicolás; Villarroel, A.; Briones, J.
- ItemThymoma associated with hypogammaglobulinaemia and pure red cell aplasia(2013) Briones, J.; Iruretagoyena B., Mirentxu; Galindo A., Héctor; Ortega, C.; Zoroquiain Vélez, José Pablo; Valbuena Mora, José Rafael; Acevedo Claros, Francisco Nicolás; Ocqueteau Tachini, Mauricio; Sanchez, C.